Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

History

Kaleido Biosciences was founded in 2017 to revolutionize the way that medicines are designed, developed, and delivered for microbiome-associated diseases. The company is developing a proprietary enzyme therapy platform that it believes can be used to treat a variety of diseases, from autoimmune disorders to influenza.

Mission

Our mission is to develop therapies that improve patient outcomes and reduce the burden of diseases mediated by the microbiome.

Vision

Our vision is to develop therapies that are effective, safe, and convenient, while advancing microbiome-based treatments to the forefront of medicine.

Key Team

Ms. Kimberly Hocknell (Sr. VP of Technical Operations)

Ms. Susan Stewart J.D., L.L.M. (Chief Regulatory Affairs ? Advisor)

Dr. Mark A. Wingertzahn Ph.D. (Sr. VP of R&D and Head of Devel.)

Recognition and Awards

Kaleido Biosciences has earned numerous awards, including a CNBC Disruptor 50 award and TIME's Top 10 Inventions of 2020.

References

https://in.investing.com/equities/kaleido-biosciences

https://finance.yahoo.com/quote/KLDO/profile?p=KLDO

https://www.crunchbase.com/organization/kaleido-biosciences-2

https://kaleido.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Ms. Kimberly Hocknell (Sr. VP of Technical Operations)

Ms. Susan Stewart J.D., L.L.M. (Chief Regulatory Affairs ? Advisor)

Dr. Mark A. Wingertzahn Ph.D. (Sr. VP of R&D and Head of Devel.)

Products/ Services

Biotechnology

Number of Employees

50 - 100

Headquarters

Bedford, Massachusetts, United States

Established

2015

Company Registration

SEC CIK number: 0001751299

Revenue

500K - 2M

Traded as

NASDAQ:KLDO

Social Media

URL

https://kaleido.com

Last updated: Tue Feb 25 2025

We value your privacy

Kaleido BioSciences

Table of content

Summary